Zoonotic

Influenza A/Astrakhan/3212/2020 (H5n8)-Like Strain (Cber-Rg8a) vaccine protects against avian influenza H5N8. This inactivated vaccine is designed for intramuscular use and is produced by Seqirus S.R.L. in the EU. It targets clade 2.3.4.4b of the H5N8 virus.

This vaccine is used to prevent influenza caused by the H5N8 strain of avian influenza. It is designed to provide immunity against the Influenza A/Astrakhan/3212/2020-like virus, particularly for those at risk of exposure. The vaccine is suitable for individuals seeking protection from zoonotic influenza strains.

After administration, the vaccine stimulates the immune system to produce antibodies against the H5N8 virus. Common effects include mild soreness at the injection site and general fatigue. Some individuals may experience mild flu-like symptoms as the body responds to the vaccine.

Store the vaccine at 2°C to 8°C and protect it from light. Do not freeze. Ensure the vaccine is administered by a healthcare professional. Individuals with known allergies to any component of the vaccine should avoid its use. Report any adverse reactions to a healthcare provider.

No specific drug interactions have been established for this vaccine. However, immunosuppressive therapies may reduce the vaccine's effectiveness. Consult a healthcare provider if you are on medications that affect the immune system. Avoid receiving other vaccines simultaneously without medical advice.